News 23andMe, Novartis team up to put Lp(a) on patients’ radar Lipoprotein(a) is well established as a risk factor for cardiovascular disease, but patients rarely get tested for it.
News Novartis preps key early breast cancer filing for Kisqali NATALEE trial readout sets up Kisqali as rival to Lilly's Verzenio as adjuvant treatment.
News Novartis pulls plug on landmark UK cholesterol trial ORION-17 study has been abandoned, with Novartis opting instead for a smaller global trial.
News Double blow for Sangamo as Novartis, Biogen exit deals The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.
News AbbVie’s Skyrizi hits the spot in refractory psoriasis Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
News Sandoz bolsters biosimilars with $400m Slovenia plant New facility will be based at Sandoz' Lek subsidiary, and employ 300 staff when completed.
News Alzheimer's biotech Korsana to go public via reverse merger By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
